Armistice Capital, LLC and Steven Boyd filed a Schedule 13G with the SEC on November 16, 2026, disclosing beneficial ownership of 6,364,000 shares of Treace Medical Concepts, Inc. common stock as of September 30, 2026.
Key Highlights
- Aggregate beneficial ownership: Armistice Capital, LLC and Steven Boyd each reported beneficial ownership of 6,364,000 shares of Treace Medical Concepts common stock.
- Percent of class: The 6,364,000 shares represent 9.79% of the outstanding class, according to the filing.
- Shared voting and dispositive power: Both reporting persons reported 0 shares of sole voting or sole dispositive power; all 6,364,000 shares are held with shared voting and shared dispositive power.
- Direct holder: The filing identifies Armistice Capital Master Fund Ltd. as the direct holder of the shares, with Armistice Capital, LLC serving as investment manager under an Investment Management Agreement.
- Event date: The date of the event requiring the filing is reported as September 30, 2026.
- Certifications: The filing states the securities "were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer."
Armistice Capital and Steven Boyd Disclose Nearly 10% Position in Treace Medical Concepts
According to the Schedule 13G filed on November 16, 2026, Armistice Capital, LLC and Steven Boyd collectively reported beneficial ownership of 6,364,000 shares of Treace Medical Concepts, Inc. (NASDAQ:TMCI) common stock, par value $0.001 per share (CUSIP 89455T109). The filing identifies the triggering event date as September 30, 2026, and was submitted jointly by the two reporting persons under Rule 13d-1.
The filing explains the ownership structure as follows: Armistice Capital, LLC is the investment manager of Armistice Capital Master Fund Ltd., which is the direct holder of the shares. Pursuant to an Investment Management Agreement, Armistice Capital exercises voting and investment power over the securities held by the Master Fund and thus may be deemed to beneficially own those shares. Steven Boyd, as the managing member of Armistice Capital, LLC, may also be deemed to beneficially own the same shares. The Master Fund "specifically disclaims beneficial ownership of the securities of the Issuer directly held by it by virtue of its inability to vote or dispose of such securities as a result of its Investment Management Agreement with Armistice Capital," according to the filing.
Neither reporting person holds any sole voting or sole dispositive power over the 6,364,000 shares; both powers are reported as shared in their entirety. The filing classifies Armistice Capital, LLC as an investment adviser and other entity (IA, OO), and Steven Boyd as a holding company and individual (HC, IN). Both parties signed the statement on November 16, 2026, with Steven Boyd signing in his capacity as Managing Member of Armistice Capital, LLC and individually.
What Was Disclosed
Armistice Capital, LLC and Steven Boyd filed a Schedule 13G disclosing a combined beneficial ownership of 6,364,000 shares, equal to 9.79% of Treace Medical Concepts, Inc. common stock, as of September 30, 2026. All voting and dispositive power is shared; none is held solely.





Please wait processing your request...